Abstract
In this mini-review, we focus on different strategies to bring nanotools specifically to cancer cells. We discuss about a better targeting of tumor, combining the characteristics of tumor environment, the increase in nanoparticles life time, the biomarkers overexpressed on cancer cells and different physical methods for non invasive therapies. Here we detail the necessity of a synergy between passive and active targeting for an actual specificity of cancer cells.
Keywords: Cancer, multiple targeting, nanoparticles, non-invasive therapies
Current Medicinal Chemistry
Title:Targeting Multiplicity: The Key Factor for Anti-Cancer Nanoparticles
Volume: 20 Issue: 15
Author(s): M. Gary-Bobo, O. Vaillant, M. Maynadier, I. Basile, A. Gallud, K. El Cheikh, E. Bouffard, A. Morere, X. Rebillard, P. Puche, P. Nirde and M. Garcia
Affiliation:
Keywords: Cancer, multiple targeting, nanoparticles, non-invasive therapies
Abstract: In this mini-review, we focus on different strategies to bring nanotools specifically to cancer cells. We discuss about a better targeting of tumor, combining the characteristics of tumor environment, the increase in nanoparticles life time, the biomarkers overexpressed on cancer cells and different physical methods for non invasive therapies. Here we detail the necessity of a synergy between passive and active targeting for an actual specificity of cancer cells.
Export Options
About this article
Cite this article as:
Gary-Bobo M., Vaillant O., Maynadier M., Basile I., Gallud A., El Cheikh K., Bouffard E., Morere A., Rebillard X., Puche P., Nirde P. and Garcia M., Targeting Multiplicity: The Key Factor for Anti-Cancer Nanoparticles, Current Medicinal Chemistry 2013; 20 (15) . https://dx.doi.org/10.2174/0929867311320150002
DOI https://dx.doi.org/10.2174/0929867311320150002 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cell Regenerative Potential Combined with Nanotechnology and Tissue Engineering for Myocardial Regeneration
Current Stem Cell Research & Therapy Medicinal Plants for Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets
Current Signal Transduction Therapy Arsenic Trioxide-based Nanomedicines as a Therapeutic Combination Approach for Treating Gliomas: A Review
Current Nanoscience Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression
Current Topics in Medicinal Chemistry Can we Target the Chemokine Network for Cancer Therapeutics?
Current Cancer Drug Targets Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy 7-Keto-Δ5-Steroids: Key-Molecules Owning Particular Biological and Chemical Interest
Mini-Reviews in Medicinal Chemistry Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters An Overview on the Role of miR-451 in Lung Cancer: Diagnosis, Therapy, and Prognosis
MicroRNA The Possibility of Novel Antiplatelet Peptides: The Physiological Effects of Low Molecular Weight HSPs on Platelets
Current Pharmaceutical Design Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry Signaling Pathways Involved in Neuron-Astrocyte Adhesion and Migration
Current Molecular Medicine PRL-3, An Emerging Marker of Carcinogenesis, Is Strongly Associated with Poor Prognosis
Anti-Cancer Agents in Medicinal Chemistry Molecular Cytogenetics and Cytogenomics of Brain Diseases
Current Genomics miR-221/222 Confers Radioresistance in Glioblastoma Cells Through Activating Akt Independent of PTEN Status
Current Molecular Medicine Somatostatin: A Hormone for the Heart?
Current Vascular Pharmacology EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo
Current Cancer Drug Targets